Additionally, the downregulation of MMP9 and LOX-1 expression by metalloproteinase inhibitors indicates that Erk1/2, LOX-1, and MMP9 could serve as potential therapeutic targets for treating peri-implantitis (Figure 5). The gene discussed is MAPK3; the disease is Peri-Implantitis.